Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net revenues	$ 3,786	$ 3,910	$ 7,447	$ 7,892
Cost of sales	1,992	2,037	3,913	4,141
Gross profit	1,794	1,873	3,534	3,750
Research and development expenses	228	248	453	501
Selling and marketing expenses	594	615	1,178	1,200
General and administrative expenses	313	242	609	532
Intangible assets impairments	51	195	199	274
Goodwill impairment	745	0	745	0
Other asset impairments, restructuring and other items	118	28	246	165
Legal settlements and loss contingencies	729	6	1,854	110
Other income	(34)	(43)	(87)	(48)
Operating income (loss)	(949)	582	(1,662)	1,015
Financial expenses, net	211	274	468	564
Income (loss) before income taxes	(1,160)	308	(2,131)	451
Income taxes (benefit)	(900)	98	(899)	159
Share in (profits) losses of associated companies, net	0	(11)	(21)	(14)
Net income (loss)	(259)	221	(1,211)	306
Net income (loss) attributable to non-controlling interests	(27)	14	(24)	21
Net income (loss) attributable to Teva	$ (232)	$ 207	$ (1,187)	$ 284
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ (0.21)	$ 0.19	$ (1.07)	$ 0.26
Diluted	$ (0.21)	$ 0.19	$ (1.07)	$ 0.26
Weighted average number of shares (in millions):
Basic	1,110	1,103	1,109	1,101
Diluted	1,110	1,109	1,109	1,108